** Shares of biopharma company Edgewise Therapeutics EWTX.O fall as much as 9.7% to a near two-month low of $12.15
** EWTX says its experimental drug showed sustained disease stabilization, up to three years, in a mid-stage study to treat two types of rare genetic disorders
** Becker and Duchenne muscular dystrophies are genetic disorders that affect muscles, causing progressive muscle wasting over time
** FDA found the mid-stage study data insufficient for accelerated approval, but said the measure of physical abilities in Becker muscular dystrophy is a valid main goal for a traditional approval - EWTX
** J.P.Morgan says FDA findings data insufficient for accelerated approval is in line with its expectations
** "We continue to remain positive on EWTX but for the most part still see the cardiovascular assets driving the most value for the stock in the mid-term" - J.P.Morgan
** Company says it plans to meet the FDA in Q4 of 2025 to discuss late stage study design
** Including session moves, stock down 51.6% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。